{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-057429","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.730698+00:00","generated_at":"2026-06-02T03:57:20.684869+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Adicet presents ADI-270 preclinical data at ASGCT; IND filing expected Q2 2024","bullets":["ADI-270 is an allogeneic anti-CD70 CAR γδ T cell therapy for solid and hematological cancers.","Preclinical data showed potent regression in ccRCC xenografts and lower CRS potential vs αβ CAR-T.","Armoring includes TGFβ receptor II inactivation and protection against alloreactive T cells.","IND submission in clear cell renal cell carcinoma (ccRCC) expected Q2 2024.","ADI-270 demonstrated both CAR-dependent and CAR-independent tumor targeting mechanisms."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-057429","json":"https://secwatch.observer/filing/0000950170-24-057429.json","markdown":"https://secwatch.observer/filing/0000950170-24-057429.md","text":"https://secwatch.observer/filing/0000950170-24-057429.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024057429/0000950170-24-057429-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024057429/acet-20240510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:57:20.684869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}